7 news items
Unveiling 18 Analyst Insights On Legend Biotech
LEGN
4 Jun 24
: With a below-average debt-to-equity ratio of 0.29, Legend Biotech adopts a prudent financial strategy, indicating a balanced approach
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
LEGN
3 Jun 24
® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
LEGN
23 May 24
® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
LEGN
14 May 24
financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Analysts work in banking
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
LEGN
13 May 24
and disclosure roadmap, and future growth strategy for good corporate citizenship
* In December 2017
v9qcplh7v
LEGN
22 Apr 24
® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS
icsnalgj681aklnfs3nc8uzs84i4c7l93
LEGN
5 Apr 24
a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI® REMS Program
- Prev
- 1
- Next